- Results published in Oxford Academic's Military Medicine Journal -- After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency -DURHAM, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication in Oxford Academic's Military Medicine of positive long-term results from its humanitarian program using Symvess to treat wartime vascular trauma injuries in Ukraine. The publication, titled "Evaluating the Safety and Efficacy of Humacyte Acellular Tissue-Engineered Vessel in a Real-World Combat Setting: A Retrospective Observational Multicenter Study," reported that trauma patients with wartime injuries treated with Symvess were observed to have a continued high rate of patency (87.1%), 100% limb salvage, and zero cases of conduit infection in 17 patients with extremity injuries followed for up to 18 months. "War is changing, and our military medicine needs to keep pace," said Oleksandr Sokolov, M.D., Ph.D., a Ukrainian vascular surgeon who treated patients with Symvess under the humanitarian program. "With the growing scale and complexity of missile- and drone-related trauma, prolonged delays and infection risk amplify the medical challenge, exposing critical gaps in timely treatment and long-term recovery. Immediate availability of a biologic conduit enables faster reconstruction and offers a practical alternative even when autologous vein is not feasible. Long-term outcomes reinforce my conclusion from using Symvess: Biologic conduits hold strong potential to advance vascular trauma care by shortening reconstruction time, reducing acute ischemia duration, lowering complication rates, and improving limb salvage."Battlefield vascular injuries are some of the most difficult for surgeons to treat because of time pressure and the potential for infection. Unlike traditional autologous vein grafts, which require harvesting a patient's vein during surgery, Symvess (acellular tissue engineered vessel (ATEVTM)) is designed to be immediately available off-the-shelf — saving critical surgical time in wartime situations. Symvess has also showed low rates of infection.The publication described the outcomes of 17 patients treated with treated with Symvess whose injuries included combat-related extremity vascular trauma from gunshots, blasts, and shrapnel. At 30 days of follow up, the primary measurement point in the study, patients treated with Symvess had incurred zero deaths, zero amputations, and zero cases of infection. The 30-day primary and secondary patency rate was 93.8%. The long-term results published for the first time in Military Medicine confirmed these earlier positive outcomes. At up to 18 months of follow up, patients were observed to have suffered zero deaths, zero infections, and zero amputations. Furthermore, Symvess demonstrated continued high levels of patency (87.1%) and no instances of immunological rejection."These outcomes not only validate the strong results we saw at the 30-day mark, but also demonstrate that patients can sustain these benefits over time, even when sustaining devastating combat wounds," said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. "Humacyte's goal has always been to improve outcomes and reduce complications for patients, and we know that goes far beyond immediate follow up. Our soldiers — and surgeons — deserve the cutting-edge in patient care, and we are excited to be offering them a new option."INDICATIONSymvess is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed ...Full story available on Benzinga.com